Successful nivolumab therapy in an allogeneic stem cell transplant child with post‐transplant lymphoproliferative disorder

Primary CNS PTLD is an extremely rare complication after allogeneic HSCT. At our centre, an 11‐year‐old patient developed nausea, vomiting, and diplopy on day +82 following HSCT. On brain MRI, multiple white matter lesions were seen. Histology showed a diffuse large B‐cell lymphoma with high load of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric transplantation 2018-12, Vol.22 (8), p.e13302-n/a
Hauptverfasser:	Kassa, Csaba, Reményi, Péter, Sinkó, János, Kállay, Krisztián, Kertész, Gabriella, Kriván, Gergely
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Antineoplastic Agents, Immunological - therapeutic use central nervous system Chemotherapy Child Cytarabine Cytarabine - therapeutic use Cytotoxicity diffuse large B‐cell lymphoma Epstein-Barr Virus Infections - complications Female Fusion Proteins, bcr-abl - genetics Graft rejection Graft-versus-host reaction Grafts hematopoietic stem cell transplantation Humans Immunosuppression Immunotherapy Injections, Spinal Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Lymphatic diseases Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Lymphoma, B-Cell - immunology Lymphoproliferative Disorders - therapy Magnetic Resonance Imaging Monoclonal antibodies Nausea nivolumab Nivolumab - therapeutic use Patients Positron emission tomography Positron Emission Tomography Computed Tomography Postoperative Period Posttransplant lymphoproliferative disorders post‐transplant lymphoproliferative disorder Remission Remission Induction Rituximab Rituximab - therapeutic use Stem Cell Transplantation Substantia alba Targeted cancer therapy Transplantation, Homologous Transplants & implants Treatment Outcome Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!